Document Detail

PDGF signaling in pulmonary arterial hypertension.
MedLine Citation:
PMID:  16200204     Owner:  NLM     Status:  MEDLINE    
The pathobiology of pulmonary arterial hypertension (PAH) includes endothelial cell dysfunction and proliferation and migration of VSMCs. As PDGF has been implicated in these processes, Schermuly et al. hypothesized that altered PDGF signaling may be involved in the vascular remodeling observed in PAH. To explore this notion further, the authors evaluated the effects of the PDGF receptor inhibitor STI571 in 2 different animal models of pulmonary hypertension. In both models, after development of pulmonary vascular disease, administration of STI571 reversed pulmonary vascular changes. These studies provide preclinical proof of concept for the clinical development of a PDGF inhibitor as a targeted therapy for PAH patients.
Robyn J Barst
Related Documents :
16113464 - Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease.
3335964 - Pulmonary hypertension in infants with bronchopulmonary dysplasia.
19076374 - The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodel...
15494704 - Pulmonary hypertension.
4012554 - Unilateral hydrocephalus combined with occlusion of the ipsilateral internal carotid ar...
15080424 - Actinomyces infection in a dog with pulmonary carcinoma.
Publication Detail:
Type:  Comment; Journal Article; Review    
Journal Detail:
Title:  The Journal of clinical investigation     Volume:  115     ISSN:  0021-9738     ISO Abbreviation:  J. Clin. Invest.     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-10-03     Completed Date:  2005-12-12     Revised Date:  2013-06-07    
Medline Journal Info:
Nlm Unique ID:  7802877     Medline TA:  J Clin Invest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2691-4     Citation Subset:  AIM; IM    
New York Presbyterian Pulmonary Hypertension Center, Columbia University College of Physicians & Surgeons, New York, New York 10032, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Disease Models, Animal
Hypertension, Pulmonary / drug therapy,  metabolism*
Piperazines / therapeutic use
Platelet-Derived Growth Factor / antagonists & inhibitors,  metabolism*
Protein Kinase Inhibitors / therapeutic use
Pulmonary Artery / metabolism*
Pyrimidines / therapeutic use
Receptors, Platelet-Derived Growth Factor / metabolism
Reg. No./Substance:
0/Piperazines; 0/Platelet-Derived Growth Factor; 0/Protein Kinase Inhibitors; 0/Pyrimidines; BKJ8M8G5HI/imatinib; EC, Platelet-Derived Growth Factor
Comment On:
J Clin Invest. 2005 Oct;115(10):2811-21   [PMID:  16200212 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mining yeast in silico unearths a golden nugget for mitochondrial biology.
Next Document:  Give me A5 for lipoprotein hydrolysis!